REGN Financial Facts

Total other income (expense): 3.08M
Net product sales: 857.47M
See Full Income Statement

Common Stock: 2K
Marketable securities: 488.03M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/2/18 Q218 $5.45$4.70 +$0.75$1.61B$1.56B = Details
11/5/19 Q319 $6.67$6.36 +$0.31$2.05B$1.99B N/A Details
5/4/17 Q117 $2.92$3.07 -$0.15$1.32B$1.3B = Details
5/5/20 Q120 $6.60$6.13 +$0.47$1.83B$1.76B N/A Details
8/4/15 Q215 $2.89$2.77 +$0.12$999M$887.81M N/A Details
2/6/20 Q419 $7.50$6.92 +$0.58$2.17B$2.11B N/A Details
5/5/16 Q116 $2.57$2.58 -$0.01$1.2B$1.18B N/A Details
5/6/21 Q121 $9.89$9.00 +$0.89$2.53B$2.55B N/A Details